Case-Based Roundtable Meetings Spotlight March 2021: Hematologic Malignancies

Dingli Compares Trial Data and Recent ASH Updates in the Newly Diagnosed Multiple Myeloma Landscape

April 06, 2021

Clinical Articles

The National Comprehensive Cancer Network considers multiple regimens to be acceptable for transplant-eligible patients with a new diagnosis of multiple myeloma. David Dingli, MD discussed the regimens that are currently available for patients.

Toxicities From Tafasitamab Monotherapy Are Less Severe After Discontinuing Lenalidomide in R/R DLBCL

April 04, 2021

Clinical Articles

The NCCN guidelines options available for patients with relapsed/refractory DLBCL include gemcitabine/oxaliplatin with or without rituximab, polatuzumab vedotin with or without bendamustine and rituximab, or the combination of bendamustine and rituximab alone.